Literature DB >> 19050053

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Kasper Aaboe1, Filip Krag Knop, Tina Vilsboll, Aage Vølund, Ulf Simonsen, Carolyn Fiona Deacon, Sten Madsbad, Jens Juul Holst, Thure Krarup.   

Abstract

OBJECTIVE: The reduced incretin effect in subjects with type 2 diabetes is accompanied by a severely impaired insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP). The K(ATP) channels of the beta-cell appear to be essential for the function of GIP in mice, and mutations in the gene encoding these channels have been linked to the development of type 2 diabetes. With this study we therefore aimed at clarifying the role of K(ATP) channel malfunction in the impaired function of GIP. RESEARCH DESIGN AND METHODS: We examined 12 subjects with type 2 diabetes using a 2-h (15 mM) hyperglycemic clamp on 4 separate days with concomitant infusion of one of the following: GIP; GIP + 10 mg sulfonylurea (SU, glipizide) taken orally 1 h before the clamp; saline + 10 mg SU; or saline alone. Blood was sampled to measure plasma concentrations of glucose, intact GIP, insulin, C-peptide, and glucagon.
RESULTS: Compared to the results of GIP alone, SU alone, or those results added together, coadministration of GIP and SU resulted in a more-than-additive increase in the peripheral insulin (P = 0.002) and C-peptide (P = 0.028) responses and furthermore, a more-than-additive increase in total (P = 0.01), early (P = 0.02), and late-phase (P = 0.02) insulin secretion.
CONCLUSION: We have demonstrated that inhibiting the K(ATP) channels of the diabetic beta-cell acutely using SU significantly increases both the peripheral insulin response to GIP and GIP-induced insulin secretion, indicating an ameliorated insulinotropic effect of GIP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050053     DOI: 10.1210/jc.2008-1731

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Approach to the Patient with MODY-Monogenic Diabetes.

Authors:  David T Broome; Kevin M Pantalone; Sangeeta R Kashyap; Louis H Philipson
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

2.  The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.

Authors:  Chelsea R Hutch; Karen Roelofs; April Haller; Joyce Sorrell; Kyle Leix; David D D'Alessio; Robert Augustin; Randy J Seeley; Thomas Klein; Darleen A Sandoval
Journal:  Diabetologia       Date:  2019-08-14       Impact factor: 10.122

Review 3.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

4.  A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.

Authors:  V K Bhat; B D Kerr; S Vasu; P R Flatt; V A Gault
Journal:  Diabetologia       Date:  2013-03-17       Impact factor: 10.122

Review 5.  New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders.

Authors:  Nigel Irwin; Peter R Flatt
Journal:  World J Diabetes       Date:  2015-11-10

Review 6.  Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.

Authors:  Jens J Holst; Filip K Knop; Tina Vilsbøll; Thure Krarup; Sten Madsbad
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

7.  GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.

Authors:  Nikolaos Mentis; Irfan Vardarli; Lars D Köthe; Jens J Holst; Carolyn F Deacon; Michael Theodorakis; Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2011-02-17       Impact factor: 9.461

Review 8.  The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?

Authors:  Ricardo Godinho; Cristina Mega; Edite Teixeira-de-Lemos; Eugénia Carvalho; Frederico Teixeira; Rosa Fernandes; Flávio Reis
Journal:  J Diabetes Res       Date:  2015-05-17       Impact factor: 4.011

9.  Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea.

Authors:  Akira Kubota; Daisuke Yabe; Akira Kanamori; Akira Kuroe; Nobuo Takahashi; Tatsuhiko Saito; Ikuro Matsuba; Koichiro Nabe; Takeshi Kurose; Yutaka Seino
Journal:  J Diabetes Investig       Date:  2014-02-11       Impact factor: 4.232

10.  A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.

Authors:  K Tatarkiewicz; D M Hargrove; C M Jodka; B R Gedulin; P A Smith; J A Hoyt; A Lwin; L Collins; L Mamedova; O E Levy; L D'Souza; S Janssen; V Srivastava; S S Ghosh; D G Parkes
Journal:  Diabetes Obes Metab       Date:  2013-08-19       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.